Quick Answer
ENANTA PHARMACEUTICALS INC reported Stockholders Equity of $64.72 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed a decrease of -49.8% in Stockholders Equity from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $110.47 million | Q4 2013: $105.58 million | Q1 2014: $101.72 million | Q2 2014: $152.95 million | Q4 2014: $193.71 million | Q1 2015: $224.22 million | Q2 2015: $228.28 million | Q4 2015: $264.28 million | Q1 2016: $266.42 million | Q2 2016: $269.01 million | Q4 2016: $268.17 million | Q1 2017: $266.01 million | Q2 2017: $260.87 million | Q4 2017: $317.58 million | Q1 2018: $333.40 million | Q2 2018: $360.90 million | Q4 2018: $426.84 million | Q1 2019: $436.21 million | Q2 2019: $448.10 million | Q4 2019: $482.29 million | Q1 2020: $485.99 million | Q2 2020: $480.56 million | Q4 2020: $452.00 million | Q1 2021: $436.03 million | Q2 2021: $417.85 million | Q4 2021: $384.38 million | Q1 2022: $358.58 million | Q2 2022: $338.02 million | Q4 2022: $300.84 million | Q1 2023: $269.38 million | Q2 2023: $237.82 million | Q4 2023: $191.88 million | Q1 2024: $166.11 million | Q2 2024: $148.92 million | Q3 2024: $128.81 million | Q4 2024: $111.82 million | Q1 2025: $93.54 million | Q2 2025: $79.28 million | Q3 2025: $64.72 million | Q4 2025: $126.59 million.
- Over the full 15 years of available data (2011 to 2025), ENANTA PHARMACEUTICALS INC's Stockholders Equity has grown by 149.0%.
- Historical annual values: Fiscal year 2025: $64.72 million | Fiscal year 2024: $128.81 million | Fiscal year 2023: $216.74 million | Fiscal year 2022: $321.33 million | Fiscal year 2021: $399.43 million | Fiscal year 2020: $455.58 million | Fiscal year 2019: $462.49 million | Fiscal year 2018: $393.68 million | Fiscal year 2017: $301.68 million | Fiscal year 2016: $269.94 million | Fiscal year 2015: $236.16 million | Fiscal year 2014: $148.65 million | Fiscal year 2013: $110.47 million | Fiscal year 2012: -$115.35 million | Fiscal year 2011: -$131.96 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: